project id: TCGA-UCEC; case submitter id: TCGA-AJ-A5DV; source center: 23; state: released; a260 a280 ratio: 1.81; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 0.05; rna integrity number: 7.0; age at index: 65; days to birth: -23892; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Alive; year of birth: 1947; age at diagnosis: 23892; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 679.0; figo stage: Stage IA; icd 10 code: C54.1; last known disease status: not reported; morphology: 8380/3; primary diagnosis: Endometrioid adenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: No; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 220; initial weight: 70.0; oct embedded: false; preservation method: Unknown; sample id: 0e933a81-858a-4a82-9ece-b56af448a510; sample submitter id: TCGA-AJ-A5DV-01A; portion id: ece80489-896e-41f4-a008-74b560037260; portion submitter id: TCGA-AJ-A5DV-01A-11; slide id: eb6105ef-8c73-4159-9125-72cb6ef88715; slide submitter id: TCGA-AJ-A5DV-01A-01-TS1; percent lymphocyte infiltration: 5.0; percent monocyte infiltration: 0.0; percent necrosis: 10.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 90.0; percent tumor nuclei: 75.0; section location: TOP;